Advisory Services Network’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-250
| Closed | -$14 | – | 3900 |
|
|
2023
Q4 | $14 | Buy |
+250
| New | +$21 | ﹤0.01% | 3841 |
|
|
2023
Q2 | – | Sell |
-250
| Closed | -$65 | – | 3987 |
|
|
2023
Q1 | $65 | Hold |
250
| – | – | ﹤0.01% | 3920 |
|
|
2022
Q4 | $53 | Buy |
+250
| New | +$63 | ﹤0.01% | 3939 |
|
|
2021
Q3 | – | Sell |
-250
| Closed | – | – | 3667 |
|
|
2021
Q2 | $0 | Buy |
+250
| New | +$442 | ﹤0.01% | 3698 |
|
|
2021
Q1 | – | Sell |
-250
| Closed | -$1K | – | 3350 |
|
|
2020
Q4 | $1K | Hold |
250
| – | – | ﹤0.01% | 3252 |
|
|
2020
Q3 | $1K | Buy |
+250
| New | +$897 | ﹤0.01% | 3521 |
|
|
2020
Q2 | – | Sell |
-250
| Closed | – | – | 3134 |
|
|
2020
Q1 | $0 | Hold |
250
| – | – | ﹤0.01% | 3450 |
|
|
2019
Q4 | $0 | Hold |
250
| – | – | ﹤0.01% | 3410 |
|
|
2019
Q3 | $0 | Hold |
250
| – | – | ﹤0.01% | 2883 |
|
|
2019
Q2 | $0 | Hold |
250
| – | – | ﹤0.01% | 2991 |
|
|
2019
Q1 | $1K | Hold |
250
| – | – | ﹤0.01% | 2499 |
|
|
2018
Q4 | $1K | Hold |
250
| – | – | ﹤0.01% | 2506 |
|
|
2018
Q3 | $1K | Hold |
250
| – | – | ﹤0.01% | 2476 |
|
|
2018
Q2 | $1K | Hold |
250
| – | – | ﹤0.01% | 2444 |
|
|
2018
Q1 | $2K | Sell |
250
-13
| -5% | -$97 | ﹤0.01% | 2432 |
|
|
2017
Q4 | $2K | Hold |
263
| – | – | ﹤0.01% | 2416 |
|
|
2017
Q3 | $2K | Buy |
263
+13
| +5% | +$110 | ﹤0.01% | 2224 |
|
|
2017
Q2 | $3K | Buy |
250
+200
| +400% | +$1.98K | ﹤0.01% | 2059 |
|
|
2017
Q1 | $1K | Buy |
+50
| New | +$568 | ﹤0.01% | 2169 |
|
Other funds holding NAVB
Advisory Services Network's NAVB Position: Q1 2024 in Review
Advisory Services Network sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2024, closing a stake of 250 shares — an estimated $14 sold.
Advisory Services Network first reported a position in NAVB in Q1 2017 and held it in 19 quarters. The position peaked at $3K in Q2 2017. 2 funds tracked by Wall St. Rank hold NAVB as of Q1 2024.
- Advisory Services Network reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2024 after selling out during the quarter.
- Advisory Services Network sold 250 Navidea Biopharmaceuticals Inc. shares in Q1 2024, an estimated $14.
- Advisory Services Network first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2017 and held it in 19 quarters.
- Advisory Services Network's Navidea Biopharmaceuticals Inc. position peaked at $3K in Q2 2017.
- 2 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2024.
Based on Advisory Services Network's 13F filing for Q1 2024, filed 6 May 2024.